2.86
price down icon4.98%   -0.15
after-market 시간 외 거래: 2.90 0.04 +1.40%
loading

Immunitybio Inc 주식(IBRX)의 최신 뉴스

pulisher
Jul 25, 2025

ImmunityBio (IBRX) Secures $80M Through Direct Offering | IBRX S - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - BioSpace

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio announces $80M registered direct offering - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors - Lelezard

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio Announces $80 Million Securities Purchase - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio's Q2 Preliminary Revenue: A Strategic Inflection Point in the Biotech Immune Therapeutics Sector - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio (IBRX) Achieves Significant Revenue Growth in Q2 2025 | IBRX Stock News - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio's Q2 Earnings and Revenue Growth: Assessing the Path to Sustainable Value Creation - AInvest

Jul 25, 2025
pulisher
Jul 24, 2025

Is ImmunityBio Inc. a good long term investmentMarket-leading profit generation - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency - MSN

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about ImmunityBio Inc. stockHigh-yield market plays - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives ImmunityBio Inc. stock priceConsistently high yield - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - Benzinga

Jul 22, 2025
pulisher
Jul 21, 2025

ImmunityBio: A High-Conviction Play on ANKTIVA's Expanding Indication and Immune-Boosting Platform - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval - Seeking Alpha

Jul 21, 2025
pulisher
Jul 20, 2025

ImmunityBio Inc. Stock Analysis and ForecastSkyrocketing returns - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 15, 2025

ImmunityBio’s Anktiva Rollercoaster: From FDA Rejection and 55% Stock Drop to Approval - TradingView

Jul 15, 2025
pulisher
Jul 14, 2025

ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView

Jul 14, 2025
pulisher
Jul 12, 2025

ImmunityBio: High Stakes On ANKTIVA's Growth Amidst FDA Friction And Financial Pressures - Seeking Alpha

Jul 12, 2025
pulisher
Jul 11, 2025

ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update - TipRanks

Jul 11, 2025
pulisher
Jul 10, 2025

Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization - MSN

Jul 10, 2025
pulisher
Jul 09, 2025

ImmunityBio Stock Surges Amid Promising Trial Updates - TipRanks

Jul 09, 2025
pulisher
Jul 09, 2025

ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

ImmunityBio Granted UK Approval for Bladder Cancer Treatment - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

ImmunityBio: D. Boral Capital Maintains Buy, Raises PT to $30 from $30 - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN

Jul 08, 2025
pulisher
Jul 07, 2025

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Lelezard

Jul 07, 2025
pulisher
Jul 07, 2025

ImmunityBio's ANKTIVA® Secures UK Approval: A Catalyst for Global Oncology Leadership - AInvest

Jul 07, 2025
pulisher
Jul 07, 2025

Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire

Jul 07, 2025
pulisher
Jul 07, 2025

ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView

Jul 07, 2025
pulisher
Jul 06, 2025

13 Stocks Under $5 With High Upside Potential - Insider Monkey

Jul 06, 2025
pulisher
Jul 04, 2025

UK Approves Intravesical Therapy Targeting Bladder Cancer - Vax-Before-Travel

Jul 04, 2025
pulisher
Jul 02, 2025

ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success - Yahoo Finance

Jul 02, 2025
pulisher
Jun 24, 2025

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

Anktiva Approved For Additional Treatment - Los Angeles Business Journal

Jun 23, 2025
pulisher
Jun 20, 2025

ImmunityBio Approves 2025 Equity Incentive Plan - TipRanks

Jun 20, 2025
pulisher
Jun 17, 2025

ImmunityBio's $10.5M Investor Deal Gets Final OK - Law360

Jun 17, 2025
pulisher
Jun 17, 2025

ImmunityBio Gets Final OK for $10.5 Million Investor Settlement - Bloomberg Law News

Jun 17, 2025
pulisher
Jun 12, 2025

ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bladder cancer treatment - pharmaphorum

Jun 12, 2025
pulisher
Jun 12, 2025

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - newswire.ca

Jun 12, 2025
pulisher
Jun 12, 2025

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze (NASDAQ:IBRX) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion - MSN

Jun 12, 2025
pulisher
Jun 08, 2025

15 Stocks That Stole The Show Last Week - Insider Monkey

Jun 08, 2025
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):